New RA drug LFD-200 enters first human safety trials

NCT ID NCT07207954

Recruiting now Disease control Sponsor: Lifordi Immunotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times

Summary

This early-phase study is testing a new drug called LFD-200 to see if it is safe and how the body processes it. The trial includes healthy adults and people with moderate to severe rheumatoid arthritis. Participants receive either the drug, a placebo, or an active comparator. The goal is to find the right dose and check for side effects, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

"ARENSIA EXPLORATORY MEDICINE" LIMITED LIABILITY COMPANY, Medical Center, Department of Clinical Trials
RECRUITING

Kyiv, 1135, Ukraine
Arensia Exploratory Medicine LLC
RECRUITING

Tbilisi, 112, Georgia
Centrum Medyczne Reuma Park
NOT_YET_RECRUITING

Warsaw, 02-691, Poland
Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E.M.
RECRUITING

Chisinau, MD2025, Moldova
MICS Centrum Medyczne Torun - MICS - PPDS
NOT_YET_RECRUITING

Torun, 87-100, Poland
Nucleus Network
RECRUITING

Melbourne, 3004, Australia

Conditions

Explore the condition pages connected to this study.

RHEUMATOID ARTHRITIS